SN vs. MXCT, NIOX, EKF, CREO, NCYT, IUG, BELL, IHC, AVO, and RUA
Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include MaxCyte (MXCT), NIOX Group (NIOX), EKF Diagnostics (EKF), Creo Medical Group (CREO), Novacyt (NCYT), Intelligent Ultrasound Group (IUG), Belluscura (BELL), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry.
MaxCyte (LON:MXCT) and Smith & Nephew (LON:SN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.
In the previous week, Smith & Nephew had 1 more articles in the media than MaxCyte. MarketBeat recorded 2 mentions for Smith & Nephew and 1 mentions for MaxCyte. Smith & Nephew's average media sentiment score of 0.67 beat MaxCyte's score of 0.67 indicating that MaxCyte is being referred to more favorably in the media.
75.0% of MaxCyte shares are owned by institutional investors. Comparatively, 58.0% of Smith & Nephew shares are owned by institutional investors. 1.2% of MaxCyte shares are owned by insiders. Comparatively, 0.2% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Smith & Nephew has a consensus price target of GBX 1,346.20, suggesting a potential upside of 37.54%. Given MaxCyte's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than MaxCyte.
Smith & Nephew received 405 more outperform votes than MaxCyte when rated by MarketBeat users. However, 68.92% of users gave MaxCyte an outperform vote while only 62.00% of users gave Smith & Nephew an outperform vote.
Smith & Nephew has a net margin of 4.74% compared to Smith & Nephew's net margin of -83.00%. MaxCyte's return on equity of 5.02% beat Smith & Nephew's return on equity.
Smith & Nephew has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
MaxCyte has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Summary
Smith & Nephew beats MaxCyte on 11 of the 17 factors compared between the two stocks.
Get Smith & Nephew News Delivered to You Automatically
Sign up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Smith & Nephew Competitors List
Related Companies and Tools
